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A prospective phase II study of pre-operative chemotherapy
then short-course radiotherapy for high risk rectal cancer:
COPERNICUS
Simon Gollins1, Nicholas West2, David Sebag-Monteﬁore3, Shabbir Susnerwala4, Stephen Falk5, Nick Brown6, Mark Saunders7,
Philip Quirke2, Ruby Ray8, Philip Parsons9, Gareth Grifﬁths10, Tim Maughan11, Richard Adams8 and Chris Hurt 8
BACKGROUND: Neoadjuvant chemotherapy (NAC) allows earlier treatment of rectal cancer micro-metastases but is not standard of
care. There are currently no biomarkers predicting long-term progression-free survival (PFS) beneﬁt from NAC.
PATIENTS AND METHODS: In this single arm phase II trial, patients with non-metastatic magnetic resonance imaging (MRI)-
deﬁned operable rectal adenocarcinoma at high risk of post-operative metastatic recurrence, received 8 weeks of oxaliplatin/
ﬂuorouracil NAC then short-course preoperative radiotherapy (SCPRT) before immediate surgery. Sixteen weeks of post-operative
adjuvant chemotherapy (AC) was planned. A pelvic MRI was performed at week 9 immediately post-NAC, before SCPRT. The
primary end point was feasibility assessed by completion of protocol treatment up to and including surgery. Secondary endpoints
included compliance, toxicity, downstaging efﬁcacy, and PFS.
RESULTS: In total 60 patients were recruited May 2012–June 2014. In total 57 patients completed protocol treatment, meeting the
primary endpoint. Compliance with NAC was much better than AC: Comparing NAC vs. AC, the median percentage dose intensity
for ﬂuoropyrimidine was 100% vs. 63% and for oxaliplatin 100% vs. 45%. Treatment-related toxicity was acceptable with no
treatment-related deaths. Post-NAC MRI showed 44 tumours (73%) were T-downstaged and 22 (37%) had excellent MRI tumour
regression grade (mrTRG 1–2). Median follow-up was 27 months with 2-year PFS of 86.2% (10 events). On exploratory analysis, post-
NAC mrTRG predicted PFS with no event among those with excellent regression.
CONCLUSION: The regimen was well tolerated with effective downstaging and encouraging PFS. mrTRG response to NAC may be a
new prognostic factor for long-term PFS, but needs validation in larger studies.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0209-4
INTRODUCTION
Approximately 15,000 patients are diagnosed with rectal cancer
annually in the UK and surgery using total mesorectal excision
(TME) is the standard of care. Using ‘short-course’ pre-operative
radiotherapy (SCPRT) of 25 Gy over 5 working days, followed by
TME within a week, reduces pelvic recurrence rates to approxi-
mately 5%.1,2.
Local recurrence reduction has not impacted on distant
metastatic relapse however, which is now the major cause of
death. Histopathological features of resected specimens predict
increased systemic recurrence risk including >5mm invasion of
disease beyond the muscularis propria (≥T3c),3,4 extra-mural
venous invasion (EMVI)5 and lymph node involvement (LN+).6
With such features, distant metastatic relapse is ~6-fold greater
than local recurrence.1,2,7 MRI scanning is the pre-treatment
investigation which can most reliably identify such features.8–10
Current UK practice, supported by NICE guidance11 is to
complete local pelvic treatment with surgery±pre-operative
radiotherapy, before considering systemic adjuvant chemotherapy
(AC). However, a more recent meta-analysis of four trials
incorporating preoperative radiotherapy suggested limited or no
beneﬁt for post-operative AC in patients receiving pre-operative
(chemo)radiotherapy.12 Using NAC as the ﬁrst received treatment,
allows earlier treatment of micrometastases and increased
compliance. However, NAC has hitherto not been established as
a standard of care in operable rectal cancer.
For tumours staged as operable, i.e., not threatening the
surgical circumferential resection margin (CRM) on pre-treatment
MRI, no downstaging is required prior to surgery and SCPRT
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followed by immediate surgery within a week, is a standard
approach.1,2 This study (COPERNICUS: Chemotherapy then Radia-
tion then Immediate Curative Surgery for operable rectal cancer)
used 8 weeks of initial NAC with oxaliplatin and 5-Fluorouracil,
then SCPRT prior to immediate surgery. It was a UK multicentre,
open-label, single arm phase II trial in patients with MRI-staged
operable rectal cancer at high risk of developing distant
metastases post-operatively.
METHODS
Eligibility
Eligible patients were adults, ECOG Performance Status 0–1, with
histopathologically conﬁrmed rectal adenocarcinoma with the
following features:
1. The inferior disease aspect was ≥4 cm from anal verge and
the superior aspect was not more superior than the anterior
S1/S2 interspace.
2. The mesorectal fascia was not threatened or involved, i.e.,
tumour was >1mm from mesorectal fascia on MRI.
3. The primary tumour was mrT3a-b (T3a: tumour invasion ≤1
mm beyond muscularis propria; T3b: invasion >1–5mm) in
the presence of either EMVI or mesorectal lymph nodes(s)/
tumour deposit(s) of any size with irregular border or mixed
signal intensity. Alternatively the primary tumour was mrT3c
(invasion >5–15mm) or T3d (invasion>15mm) or T4
(invasion of visceral peritoneum for tumours with a
component above peritoneal reﬂection was permitted
although invasion of other organs was not), regardless of
EMVI or nodal status. Low tumours did not involve levator
ani or anal sphincters.
4. CT scan of chest and abdomen excluded metastatic disease.
Haematological, renal, and hepatic biochemical indices were
satisfactory. All patients provided written informed consent to a
medical doctor.
Treatment
NAC. Four, 14-day cycles of Oxaliplatin/5-Fluorouracil (OxMdG)
were administered via a central venous catheter (day 1 oxaliplatin
85mg/m2 plus levofolinic acid 175 mg over 2 h, then 5-
Fluorouracil 400 mg/m2 bolus, then 5-Fluorouracil 2400mg/m2
continuous infusion over 46 h).
Radiotherapy. Within 14 days following completion of the last 2-
weekly cycle of chemotherapy, i.e., within 15–28 days following
the ﬁrst day of the last cycle of chemotherapy, patients
commenced treatment with SCPRT. Before commencing SCPRT,
haematological and gastrointestinal toxicities should have
resolved to NCI CTCAE ≤ grade 1.
COPERNICUS full Radiotherapy Guidelines are included in the
Supplementary Material. Brieﬂy, pelvic radiotherapy was planned
using oral and intravenous contrast CT simulation with recom-
mended 3mm CT slices. 25 Gy in 5 daily fractions, prescribed
according to recommendations of the International Commission
on Radiation Units and Measurements (ICRU-50), was delivered
over 5–7 days Monday to Friday as a 3D, conformally planned
single-phase treatment, usually with four radiotherapy ﬁelds.
Gross tumour volume (GTV) was deﬁned using the diagnostic MRI
scan and included all macroscopic tumour and any intervening
normal rectal wall. Clinical target volume (CTV) was deﬁned in two
parts (CTVA and CTVB) and then combined to form the Final CTV
(CTVF). CTVA consisted of GTV with a 1 cm margin grown in all
directions. CTVB included the mesorectum, the presacral and
internal iliac nodal structures. CTVB superior limit was the more
superior of 2 cm above the most superior limit of GTV, or the S2/3
interspace. CTVB inferior limit was the more inferior of 2 cm
inferior to the most inferior limit of GTV, or the superior limit of
puborectalis. The ﬁnal CTV (CTVF) was derived by combining CTVA
and CTVB. The planning target volume (PTV) was derived by
adding a 1 cm margin to CTVF in all directions. Veriﬁcation with
cone-beam CT or electronic portal imaging was used on the ﬁrst 3
fractions of radiotherapy. Radiotherapy quality assurance was
carried out via the UK National Cancer Research Institute
Radiotherapy Trials Quality Assurance Group (NCRI RTTQA). Pre-
accrual quality assurance included completion of two benchmark
cases: a delineation exercise and a planning exercise on a pre-
contoured patient. These assessments were identical to those
which had previously been deﬁned for the ongoing UK phase III
ARISTOTLE trial. Gaining previous approval for ARISTOTLE also
conferred a centre with COPERNICUS approval. For on-trial, as a
minimum, QA consisted of prospective individual case review
(both contours and treatment plan) for the ﬁrst patient from each
radiotherapy delivery site. Radiotherapy Protocol compliance of
the remaining patients was reviewed using a pre-designed Plan
Assessment Form which captured clinically relevant dose–volume
metrics.
Surgery. Surgery was recommended within 7 days of the last
fraction of SCPRT although a gap of 14 days was acceptable.
AC. Between 6 and 8 weeks following the date of surgery,
patients commenced eight, 14-day cycles of AC using OxMdG,
although alternatively a combination of oxaliplatin and capecita-
bine could be used (a 14-day schedule of oxaliplatin 85mg/m2 IV
day one followed by oral capecitabine at 1000mg/m2 twice daily
for 9 days).
Assessments
Toxicity was assessed as per US National Cancer Institute’s
Common Terminology Criteria for Adverse Events (CTCAE version
4.03) at the end of each treatment cycle and at the end of SCPRT.
Capecitabine compliance was assessed by tablet count at each
visit. An MRI was performed at 9 weeks (post NAC, pre-SCPRT) to
assess downstaging and tumour regression grade (mrTRG) using a
5-point scale.13 Resection specimens were evaluated by local
histopathologists as per detailed trial-speciﬁc guidelines (see
appendix E of the trial protocol, included as Supplementary
Material). The 5-point Dworak system was used to assign a
pathological tumour regression grade (pTRG), mirroring mrTRG.14
Sites sent formalin-ﬁxed, parafﬁn-embedded blocks of pre-
treatment and surgical resection material to Leeds Institute of
Cancer and Pathology, University of Leeds. All glass haematoxylin
and eosin stained slides were also sent from the biopsy and
resection specimens for scanning to create a permanent record
(http://www.virtualpathology.leeds.ac.uk/clinical/colorectal/
copernicus) and facilitate central review of pTRG and tumour cell
density (TCD) calculation.15
TNM Classiﬁcation of Malignant Tumours 5th edition was used
for histopathological staging. Histopathological substages T3a-d
were deﬁned similarly to those used for MRI. Pathological
complete response (ypT0ypN0) was conﬁrmed as follows: Where
tumour cells could not be found on the ﬁrst assessment of up to
ﬁve blocks of tumour, the whole area of the tumour/ﬁbrotic scar
was embedded and examined. If no tumour cells could be seen
following assessment of these extra blocks, then three deeper
levels were taken and examined from each tumour/ﬁbrotic scar
block. ypT0ypN0 was conﬁrmed if no tumour cells were identiﬁed.
There were no ypT0N+cases.
TCD15 was measured by digitally scanning the glass haemotox-
ylin and eosin-stained slides at ×200 magniﬁcation and annotating
around the tumour. Approximately 300 random points within this
area were then manually assessed to determine the underlying
tissue components and calculate the TCD. For resected tumour
TCD was expressed as either the ‘whole tumour’ TCD when the
outlining included scar, or alternatively the area of the greatest
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TCD when annotating a 3 × 3mm2 area in the region of apparent
greatest residual tumour.
Post-operative morbidity was assessed at 30 days post-surgery.
Patients were followed up to assess disease status at 6 months
and 12 months following surgery, with a CT scan mandated at
12 months. Investigations and follow-up beyond 12 months were
done as per institutional standard.
Statistics
This was a single arm phase II trial. The primary endpoint
was completion of protocol treatment up to and including
surgery deﬁned as starting NAC, and completing SCPRT and
surgery. If >92% (as was found in CR07,2 and not <80%, of
patients completed surgery then it would warrant further
investigation in the Phase III setting. Based on an A’Hern
design16 looking at proportion of patients completing surgery
and setting p0= 0.80, p1= 0.92, 90% power, alpha= 0.1, 57
patients were required (with 50 patients completing surgery
counting as success).
Secondary endpoints included compliance, toxicity, histopatho-
logical and radiological assessment of downstaging efﬁcacy, and
PFS. Exploratory analyses investigated the relationship between
measures of downstaging efﬁcacy and PFS.
Data were analysed according to a pre-speciﬁed analysis plan
using the Stata SE 14 statistical package. All analyses were by
intention to treat except toxicity analyses, which were conducted
only in those patients who had some treatment during the related
treatment phase, and the surgical complications analysis only in
those who had surgery. Clopper-Pearson exact binomial method
was used to calculate conﬁdence intervals for the primary
endpoint. We calculated % of total dose (actual total dose divided
by protocol total dose) and % dose intensity (actual dose intensity
[dose per unit time] divided by protocol dose intensity) for each
protocol drug as measures of compliance. Baseline and pre-
surgical weight was compared using a Wilcoxon signed rank test.
Univariable ordinal regression was used to look for associations
between categorical (number of baseline MRI risk factors (out of
T≥3c or N1-2 or EMVI+), mrTRG, pTRG,) and continuous variables
(TCD). We calculated progression free survival (PFS) from date of
registration to when a failure event (death, or conﬁrmed evidence
of distant metastases or loco-regional progression) occurred.
Patients who were event-free were censored at the time they were
last known to be event free. Follow-up time distribution was
estimated using the reverse Kaplan–Meier method17 with patients
censored at date of death or last trial assessment. We estimated
event time distributions with the Kaplan–Meier method and
Assessed for eligibility (n=147)
Excluded (n=87)
Not meeting inclusion criteria (n=69)
Disease metastatic (n=25)
Other aspect of disease e.g.wrong stage, not measurable (n=22)
Patient fitness/co-morbidity (n=8)
Previous malignancy (n=4)
Clinician choice (n=4)
Other (n=4)
Unknown (n=2)
Declined to participate (n=18)
Received cycle 1 (n=60)
Registered (n=60)
Received cycle 2 (n=59)
Stopped chemo due
to pericarditis (n=1)
Received cycle 3 (n=58)
Received cycle 4 (n=57)
Withdrew 
Chest pain, had LCPRT
(n=1)
Stopped chemo due
to patient fitness
(n=1)
Received SCPRT (n=58)
Withdrew 
Complete clinical 
response, had LCPRT
(n=1)
Withdrew 
Patient choice (n=1)
Had surgery (n=57)
Received cycle 5 (n=45)
Received cycle 6 (n=44)
Received cycle 7 (n=41)
Received cycle 8 (n=40)
Received cycle 9 (n=37)
Received cycle 10 (n=36)
Received cycle 11 (n=34)
Received cycle 12 (n=29)
Withdrew
Patient choice (n=3)
Clinician choice/poor PS
after surgery (n=9)
Withdrew 
Patient choice (n=1)
Clinician choice (n=15)
Fig. 1 Participant ﬂow diagram
A prospective phase II study of pre-operative chemotherapy then. . .
S Gollins et al.
3
looked for relationships between PFS and potential predictors
using Cox regression in univariable models.
RESULTS
In total 60 patients were enroled from 14 UK centres between 25
May 2012 and 11 June 2014 (Fig. 1). At the time of analysis, all
patients had completed at least 1 year of post-surgical follow-up
or withdrawn from the study. Patient and tumour baseline
characteristics are shown in Table 1. Pre-treatment MRI showed
that 35 (58%), 14 (23%) and 11 (18%) patients had 1, 2 or 3 high-
risk features, respectively.
Toxicities
Toxicities during neoadjuvant (end of cycle 1 to post SCPRT
assessment) and adjuvant (end of cycle 5 to end of cycle 12)
treatment periods are shown in Table 2. The rate of any grade 3+
toxicity was similar in each treatment period: neoadjuvant 24/60
(40%) and adjuvant 15/45 (33%), with neutrophil count decrease
being the most common toxicity in each case: 12/60 (20%) and 5/
45 (11%), respectively. There were no deaths during treatment
(including the post-surgical period). There was no evidence of a
difference between baseline (median: 84.1 kg, IQR: 78.1–92.1) and
pre-surgical (median: 85.3 kg, IQR: 76.1–92.7) weight (z= 0.796, p
= 0.426, n= 56). Post-surgical complications within 30 days are
shown in Supplementary Online Table 1 including three patients
(5%) who suffered an anastomotic dehiscence. Out of the 57
patients who had surgery, 49 (86%) were discharged within
30 days, a median of 7 (IQR: 6–11) days after surgery.
Compliance
Compliance with NAC was much better than AC, as shown in
Fig. 2. In total 45/60 (75%) of patients started AC. 22/60 (37%) of
patients switched from 5FU to capecitabine during AC. The
median percentage total dose and dose intensity of 5FU/
capecitabine was 100 (IQR: 97–100) and 100 (IQR: 75–100)
respectively during NAC and 80 (IQR: 5–88) and 63 (IQR: 5–81)
respectively during AC. The median percentage total dose and
dose intensity of oxaliplatin was 100 (IQR: 93–100) and 100 (IQR:
75–100) respectively during NAC and 58 (IQR: 0–98) and 45 (IQR:
0–77) respectively during AC.
Of the 58 patients who started SCPRT (see Fig. 1), the median
time from the start of last cycle of NAC to the start of SCPRT was
24 days (IQR: 19–27, Range: 13–103), all patients received SCPRT at
full protocol dose, and only 1 patient experienced a non-logistical
delay during SCPRT (due to rheumatoid arthritis ﬂare-up).
In total 57/60 (95%, 90% CIs: 88–99) patients had surgery, the
majority (43, 75%) had an anterior resection, 3 (5%) a Hartmann’s
resection and 11 (19%) an abdominoperineal excision. The median
time from ﬁnishing pre-surgical treatment to having surgery was
7 days (IQR: 4–12, Range: 1–34, n= 57). The median time from
surgery to start of adjuvant chemotherapy was 63 days (IQR:
53–79, Range: 40–133, n= 45). Three patients did not have
surgery: one patient refused surgery because of anxiety with no
recurrence at 18 months post-registration. Contrary to protocol,
two patients received long-course chemoradiation rather than
SCPRT. One of these later underwent a successful resection and in
the other a ‘watch and wait’ approach was adopted with no
recurrence at 17 months post-registration.
All 9 radiotherapy centres passed pre-accrual QA prior to
entering patients into the trial. Of the 58 patients having SCPRT,
the ﬁrst patient’s contours and plans from each radiotherapy
centre underwent prospective review prior to radiotherapy
starting. Only one centre was required to undergo repeat
prospective review because they submitted their ﬁrst patient’s
data for review after the patient had started their RT. One
additional centre was requested to make some minor contouring
amendments prior to RT—this was completed successfully and a
Table 1. Baseline characteristics and 9 week MRI results
Baseline 9 weeks
n (%)a n (%)a
Patients enroled
N 60
Age (years)
Median (IQR, range, n) 63 (56.5–70,
38–79, 60)
Gender
Male 44 (73.3)
Female 16 (26.7)
ECOG performance status
0 55 (91.7)
1 5 (8.3)
Predominant differentiation
of primary tumour
Well 5 (8.3)
Moderate 49 (81.7)
Poor 2 (3.3)
Unknown 4 (6.7)
Time from MRI scan to
registration (weeks)
Median (IQR, range, n) 3.7 (2.6–4.6,
0–5.9, 60)
before reg
9.4 (8.7–10,7.4–12.4,58)
after reg
MRI–Craniocaudal length
(mm)
Mean (SD, range, n) 49 (11.9,
28–80, 58)
34.3 (13.5, 7–70, 52)
MRI–Height from anal verge
(mm)
Mean (SD, range, n) 79 (21.5,
40–140, 58)
82.9 (21.8, 35–140, 52)
MRI T Stage
T0 4 (7)
T1 1 (2)
T2 1 (1.7) 28 (47)
T3a 17 (28.3) 6 (10)
T3b 24 (40) 13 (22)
T3c 14 (23.3) 4 (7)
T3d 1 (1.7) 0 (0)
T4 3 (5) 0 (0)
Missing 0 (0) 4 (7)
MRI N Stage
N0 7 (11.7) 38 (63)
N1 39 (65) 18 (30)
N2 14 (23.3) 2 (3)
Missing 0 (0) 2 (3)
MRI M Stage
M0 60 (100) 58 (97)
Missing 0 (0) 2 (3)
MRI–CRM involvement
Clear (>1mm) 59 (98.3) 57 (95)
Missing data 1 (1.7) 2 (3)
MRI–Extramural venous
invasion
Positive 25 (41.7) 9 (15)
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further patient review was not necessary. The remaining 48 plans
were assessed using the Plan Assessment Form. All plans were
considered acceptable.
Efﬁcacy
Radiological downstaging. Table 1 shows the results from the
post-NAC week 9 MRI compared to baseline MRI. T Stage was
downstaged in 44/60 (73%), unchanged in 12/60 (20%), and
missing for 4/60 (7%) of patients. N Stage was downstaged in 36/
60 (60%), unchanged in 22/60 (37%), and missing for 2/60 (3%) of
patients. There was no recorded progression in either T or N stage
during NAC. 22 tumours (37%) showed excellent regression
(mrTRG 1-2). EMVI reduced from 25/60 (42%) pre-operatively to 9/
60 (15%) on the week 9 MRI.
Pathological downstaging. Surgical procedure information and
pathology results are shown in Table 3. In total 7/57 (12%) patients
were found to have had a complete pathological response,
conﬁrmed by a central review that included a check of the
number of deeper levels cut on the entirely embedded scars.
Compared to baseline MRI, histopathological (ypT) T stage was
downstaged in 42/57 (74%), unchanged in 11/57 (19%) and
upstaged in 4/57 (7%) of patients. Histopathological (ypN) N stage
was downstaged in 37/57 (65%), unchanged in 16/57 (28%), and
upstaged in 4/57 (7%) of patients. The incidence of histopatho-
logical EMVI+ in the resected specimen (11/57: 19%) was similar
Table 1 continued
Baseline 9 weeks
n (%)a n (%)a
Negative 35 (58.3) 49 (82)
Missing 0 (0) 2 (3)
Number of baseline MRI risk
factors out of T≥3c or N1-2
or EMVI+
3 11 (18.3)
2 14 (23.3)
1 35 (58.3)
MRI tumour regression
grade
Complete regression
(TRG1)
6 (10)
Good regression (TRG2) 16 (27)
Moderate regression
(TRG3)
15 (25)
Slight regression (TRG4) 12 (20)
No regression (TRG5) 7 (12)
Missing data 4 (7)
aUnless otherwise indicated, denominator is 60
Table 2. CTCAE v4.02 grade 3+ toxicity in patients during neoadjuvant (week 1 to post SCPRT assessment) and adjuvant (post cycle 5 to post cycle
12 assessment) treatment
System organ class Adverse event Neoadjuvant n (%)a Adjuvant n (%)b
Any Any 24 (40) 15 (33)
Cardiac disorders Pericarditis 1 (2) 0 (0)
Gastrointestinal Abdominal pain 0 (0) 2 (4)
Diarrhoea 1 (2) 3 (7)
Dyspepsia 1 (2) 0 (0)
Gastritis 1 (2) 0 (0)
Nausea 1 (2) 1 (2)
Rectal obstruction 0 (0) 1 (2)
Stomatitis 2 (3) 0 (0)
General disorders and administration site conditions Injection site reaction 0 (0) 1 (2)
Localised oedema 1 (2) 0 (0)
Infections and infestations Upper respiratory infection 1 (2) 2 (4)
Injury, poisoning and procedural complications Vascular access complication 1 (2) 0 (0)
Investigations Neutrophil count decreased 12 (20) 5 (11)
Platelet count decreased 2 (3) 1 (2)
Weight loss 0 (0) 1 (2)
White blood cell decreased 1 (2) 1 (2)
Metabolism and nutrition disorders Hyperuricemia 0 (0) 1 (2)
Nervous system disorders Neuropathy 1 (2) 0 (0)
Syncope 1 (2) 0 (0)
Psychiatric disorders Agitation 1 (2) 0 (0)
Anxiety 1 (2) 0 (0)
Respiratory, thoracic and mediastinal disorders Cough 1 (2) 0 (0)
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysesthesia syndrome 0 (0) 1 (2)
Rash 1 (2) 0 (0)
Vascular disorders Thromboembolic event 2 (3) 0 (0)
adenominator N= 60 (all patients starting neoadjuvant chemotherapy) bdenominator N= 45 (all patients starting adjuvant chemotherapy)
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to that shown on the week 9 MRI (9/58: 16%, Table 3).
Likewise waterfall plots of TCD showed a marked response
(Supplementary Online Fig. 1). Median biopsy TCD was 37.2%,
reduced to 8.7% in resection whole TCD.
Relationship between mrTRG and resection pathology. We found a
signiﬁcant association between mrTRG and pTRG (χ2= 26.5, p=
0.048), resection greatest TCD (ordinal regression z=−3.77, p <
0.001), and resection whole TCD (z=−3.77, p<0.001) in the 54
patients with non-missing data.
Relationship between pTRG and TCD. Univariate ordinal regres-
sion showed no evidence of a relationship between pTRG and the
number of baseline MRI risk factors (z=−0.06, p= 0.951) or biopsy
TCD (z= 0.29, p= 0.774, n= 57), but strong relationships between
pTRG and resection greatest TCD (z=−5.70, p < 0.001, n= 57),
resection whole TCD (z=−5.41, p < 0.001, n= 57), and resection
whole TCD as a percentage of biopsy TCD (z=−4.03, p < 0.001, n
= 57).
PFS. The median follow-up for PFS was 27.3 months (IQR:
22.3–31.1). Of the 60 patients enroled in the trial, 10 had
progression (8 distant (6 lung, 1 liver, 1 small bowel), and 2 local
recurrences) at the time of analysis. The PFS rate at 2 years was
86.2% (95% CIs: 74.3–92.9). One patient died after 2.3 years.
Relationship between measures of downstaging and PFS. Strik-
ingly, none of the 22 patients with an excellent response to NAC
on the week 9 MRI (mrTRG 1–2) had a progression event. All 10
progression events occurred in the 34 patients with mrTRG 3–5
(Fig. 3a).
Univariate cox regression showed a weak association between
pTRG (when split by complete/good vs moderate/minimal/none)
and PFS (see Fig. 3b): HR= 4.76 (95% CIs: 0.60–37.61, p= 0.139).
When TCD was included as a continuous variable in a univariate
cox regression, there was some evidence that resection greatest
TCD was associated with worse PFS (HR 1.03, 95% CI: 1.00–1.07, p
= 0.066) but evidence for association with other TCDs was weak:
biopsy TCD HR 1.01 (95% CI: 0.96–1.06, p= 0.725), resection whole
TCD HR 1.04 (95% CI: 0.99–1.10, p= 0.137).
DISCUSSION
This study has demonstrated the safety and feasibility of
introducing NAC prior to SCPRT and surgery. There was a
strikingly better compliance to NAC versus AC, rates of Grade
3+ toxicity were acceptable (≤40%) and post-operative complica-
tions were similar to what might be expected with SCPRT alone
followed by immediate surgery.2
In keeping with our ﬁndings a randomised phase II study (GCR3)
of neoadjuvant versus post-operative adjuvant oxaliplatin and
capecitabine in 108 patients treated with chemoradiation and
surgery, demonstrated less toxicity (p= 0.0004) and better
compliance (p < 0.0001) for NAC compared with AC.18
In attempting to successfully treat micro-metastases, which are
the main cause of rectal cancer death, there is thus a strong
rationale for assessing initial NAC in trials powered for 3-year PFS.
A further potential beneﬁt of NAC is earlier closure of temporary
% Total dose – neoadjuvant % Dose intensity – neoadjuvant 
% Total dose – adjuvant % Dose intensity – adjuvant 
100
80
60
40
20
100
80
60
40
20
100
80
60
40
20
0
100
80
60
40
20
0
Percentiles
100806040200
Percentiles
100806040200
Percentiles
100806040200
Percentiles
100806040200
Oxaliplatin 5FU Oxaliplatin 5FU
Oxaliplatin Capecitabine/5FU Oxaliplatin Capecitabine/5FU
a b
dc
Fig. 2 Total dose and dose intensity curves for neoadjuvant and adjuvant chemotherapy
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stomas. The quality of surgery in the current study was good, with
74% of specimens resected in the mesorectal plane, suggesting
that NAC then SCPRT is safe and not compromising surgical
quality. The overall PFS rate at 2 years of 86.2% in this MRI-
selected high risk group of patients is encouraging.
Only one previous observational study examined NAC then
SCPRT then surgery, recruiting 67 patients with cT3-4 tumours
from 1997 to 2008.19 Patients received eight weeks of NAC (5-FU-
based for the ﬁrst 28 patients then oxaliplatin-5FU for the
subsequent 39), followed by SCPRT (20 Gy in ﬁve fractions) then
surgery within the following week. Although histopathological
downstaging was seen in 51% of patients, no pCR was reported.
In contrast the current regimen suggested greater anti-tumour
activity, with superior T-downstaging and 7 tumours (12%)
showing a ypT0ypN0 pCR. Reasons for this discrepancy may
include the higher radiotherapy dose used in the current study (25
Table 3. Surgery and pathology
n (%)a
Surgical procedure
Abdominoperineal excision 11 (19)
Anterior resection 42 (74)
Hartmann’s 3 (5)
Anterior resection & prophylatic TAH &
BSO
1 (2)
Does the patient have a defunctioning
stoma
Yes 43 (75)
No 11 (19)
Missing 3 (5)
If yes, what type?b
Ileostomy 32 (74)
Colostomy 10 (23)
Missing 1 (2)
If yes, intention?b
Temporary 29 (67)
Permanent 14 (33)
Post-operative pathology
pT0 7 (12)
pT1 3 (5)
pT2 19 (33)
pT3a 9 (16)
pT3b 10 (18)
pT3c 8 (14)
pT4a 1 (2)
pN0 39 (68)
pN1 13 (23)
pN2 5 (9)
R0 (>1mm from margin) 56 (98)
R1 (≤1mm from margin) 1 (2)
Number of lymph nodes examined
Median (IQR, range, n) 19 (14–25, 1–48, 57)
Number of lymph nodes positive
0 39 (68)
1–2 11 (19)
3–5 6 (11)
13 1 (2)
Extramural venous invasion
Yes 11 (19)
No 46 (81)
Distance to CRM (mm)
Median (IQR, range, n) 12 (6–15.5, 1–50, 47)
pTRG
No regression 7 (12)
Minimal regression 17 (30)
Moderate regression 14 (25)
Good regression 12 (21)
Complete regression 7 (12)
Plane of resection of mesorectum
Muscularis propria 2 (4)
Intramesorectal 6 (11)
Mesorectal 42 (74)
Table 3 continued
n (%)a
Missing 7 (12)
Plane of abdomnio-perineal excisionc
Levator 3 (27)
Sphincteric 5 (46)
Intrasphincteric/perforated 0
Missing 3 (27)
Distance of tumour to distal surgical margin
(mm)
Median (IQR, range, n) 30 (20–50, 5–100, 48)
Involvement of distal margin?
No 54 (95)
Missing 3 (5)
Distance of tumour to proximal surgical
margin (mm)
Median (IQR, range, n) 182.5 (120–255, 50–460,
46)
Involvement of proximal margin?
No 53 (93)
Missing 4 (7)
Is there any evidence of tumour perforation?
Yes 2 (4)
No 53 (93)
Unknown 2 (4)
Peritoneal involvement? (ypT4b disease)
Yes 1 (2)
No 50 (88)
Missing 6 (11)
Biopsy TCD
Median (IQR, range, n) 37.2 (22.7–44.2, 6.3–58.5,
59)
Resection greatest TCD
Median (IQR, range, n) 21.4 (2.7–39.1, 0–59.9,
57)
Resection whole TCD
Median (IQR, range, n) 8.7 (1.3–16.1, 0–38.2, 57)
Resection whole TCD as % of biopsy TCD
Median (IQR, range, n) 19.4 (3.2–53.8, 0–468.9,
57)
aunless otherwise indicated, denominator N= 57 bdenominator N= 43, i.e.,
those with defunctioning stoma cdenominator N= 11, i.e., those who had
abdominoperineal excision
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vs. 20 Gy), the use of both oxaliplatin and 5FU for all patients, and
MRI selection (no MRI staging was used in Ciammella et al.19).
The Dutch TME trial failed to demonstrate any histopathological
T stage downstaging with SCPRT alone of 5 × 5 Gy followed by
surgery within a week.20 However very signiﬁcant downstaging
was seen in the current study, so NAC appears of importance for
the observed anti-tumour activity. The week 9 MRI demonstrated
conclusively that OxMdG NAC alone produced marked tumour
downstaging.
The relative contributions of NAC and SCPRT to histopatholo-
gical downstaging remain unclear and are potentially complex.
Theoretical advantages to NAC before radiotherapy include
improved tumour response through downstaging and increased
oxygenation/radiosensitisation. Theoretical disadvantages include
delayed radiotherapy and selection of radioresistant clones.21
There are currently no phase III studies examining NAC then
SCPRT. The use of SCPRT for rectal cancer is decreasing in the UK.
However, this trend could change dependent on the results of the
phase III RAPIDO trial (NCT01558921), which completed accrual of
920 patients in June 2016. This randomised patients with locally
advanced rectal cancer to standard chemoradiation then surgery,
versus an experimental arm of SCPRT followed by NAC then
surgery.
A meta-analysis has highlighted limited efﬁcacy of AC following
preoperative radiotherapy.12 Several factors potentially reduce the
effectiveness of AC in rectal cancer. Morbidity from surgery and
radiotherapy can delay initiation and reduces tolerance of AC. In
addition, the presence of post-operative stomas, expected in
approximately 80% of patients,22 can impair or stop chemother-
apy delivery altogether because of diarrhoea.23 The high response
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rate to initial NAC in the current study suggests that future
comparison of pre- versus post-operative chemotherapy may be
justiﬁed.
The UK has a high standard of routine pelvic MRI reporting
following UK-wide initiatives such as the LOREC educational
programme.24 MRI-deﬁned TRG has been suggested to predict
survival outcome post long-course chemoradiation13 and is
increasingly reported in routine clinical practice following pre-
operative chemoradiation. Theoretically the baseline MRI scan
could over-stage some patients in terms of their high-risk factors,
leading to over-treatment. The loss of high-risk histopathological
features in the eventually-resected specimen, due to the down-
staging effect of neoadjuvant chemotherapy, makes if difﬁcult to
quantify this risk, although because of previously-reported strong
correlation of MRI and histopathological high-risk features, we
consider this risk low.8–10
Response to NAC assessed by MRI by RECIST criteria, was
described in the EXPERT trials, which used 12 weeks oxaliplatin/
capecitabine before chemoradiotherapy and then surgery in
186 subjects. The radiological response rate was 63%, and only
2 patients (1%) progressed,25–27 echoing current ﬁndings.
Pathological TRG following chemoradiation and surgery has
recently been suggested to be both a prognostic factor and an
individual patient level surrogate for disease-free survival within
the randomised CAO/ARO/AIO-04 trial.28
To our knowledge mrTRG has not been described in rectal
cancer post-NAC alone, as in the current study. We found that
mrTRG was well correlated with pTRG and resection TCD but
better than them at predicting PFS, although a hazard ratio could
not be calculated due to no events in the 22 excellent responders.
The use of week 9 MRI post-NAC but before SCPRT most directly
assessed the effect of NAC, without the addition of radiotherapy,
which potentially affected subsequent pTRG and resection TCD.
However, because of an overall limited number of events, it was
not possible to perform multivariable regression to assess whether
or not mrTRG remained a strong independent predictive marker
for PFS, nor was it possible to assess whether or not it signiﬁcantly
outperforms other potential predictors such as pathological
response.
Histopathological TCD provides a novel continuous measure of
tumour regression, as opposed to the categorical pTRG measures,
such as Dworak. Hitherto, TCD has not been reported in assessing
rectal cancer response but here clearly demonstrated marked
response, which correlated strongly with Dworak pTRG. Possibly
relevant to future studies, the area of greatest residual TCD
appeared to be more strongly associated with PFS than both
whole tumour TCD (including scar) and pTRG. However, statistical
power was limited due to the limited patient numbers and events.
In conclusion, at present there are no established biomarkers in
patients receiving NAC that can predict those patients who may
demonstrate a PFS beneﬁt compared to those who will not. Our
ﬁndings suggest that mrTRG following NAC may be a prognostic
factor for PFS and are hypothesis-generating but need validation
in future, larger studies. If conﬁrmed, mrTRG has potential for use
as a short-term surrogate in future studies of intensiﬁed NAC
treatment strategies aimed at improving PFS in this high-risk
group of patients.
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